Related Experiment Video
Updated: Jul 16, 2026
07:31
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
Published on: May 3, 2021
Ezrin expression predicts survival in stage IIB osteosarcomas
Min Suk Kim1, Won Seok Song, Wan Hyeong Cho
1Department of Pathology, Korea Cancer Center Hospital, Seoul, Korea.
Clinical Orthopaedics and Related Research
|March 14, 2007
Summary
Ezrin protein expression in osteosarcoma biopsy samples may predict patient outcomes. Higher ezrin levels correlated with increased distant metastasis, suggesting its role in osteosarcoma progression.
Area of Science:
- Oncology
- Molecular Biology
- Biomarker Discovery
Background:
- Ezrin, a cytoskeleton linker protein, is implicated in solid tumor metastasis.
- Limited clinical data exists on ezrin's role in osteosarcoma prognosis.
Purpose of the Study:
- To investigate the association between ezrin expression and prognosis in osteosarcoma patients.
- To evaluate ezrin as a potential predictive biomarker for osteosarcoma outcomes.
Main Methods:
- Retrospective analysis of 64 Stage IIB osteosarcoma patients (1995-2000).
- Immunohistochemical staining of ezrin expression on biopsy tissue microarrays.
- Comparison of ezrin levels with clinicopathologic variables and patient survival outcomes.
Main Results:
- Ezrin expression was observed in 51.6% of patients.
- Patients with ezrin expression had a higher rate of distant metastasis (66.7%).
- Multivariate analysis identified ezrin expression and histologic response to chemotherapy as predictors of disease-free survival.
Conclusions:
- Ezrin expression in osteosarcoma biopsy specimens is a significant predictor of disease-free survival.
- Ezrin shows promise as a prognostic biomarker for patients with osteosarcoma.
- Further research is warranted to validate ezrin's role in osteosarcoma metastasis and treatment response.
